GEN Exclusives

More »

GEN News Highlights

More »
Apr 14, 2010

Tissue Solutions and HUNT Biosciences Come Together to Promote Norwegian Study and Biobank

  • Biomarker discovery and validation company HUNT Biosciences signed a collaboration with Scotland-based Tissue Solutions, which provides biological samples for the pharma and diagnostics industries. The partnership aims to promote the HUNT Study and its associated biobank.

    Over the last 25 years the HUNT Study has collected blood samples and associated phenotypic, lifestyle, genetic, and environmental data from the population of Norway’s Nord Trøndelag region. As part of the CONOR (Cohort of Norway) project, The Hunt Study involves a regional cohort of over 100,000 individuals and comprises over 3,000 clinical variables. The resource is a satellite of the Norwegian University of Science and Technology (NTNU) in Trondheim and is sited at  the new National Biobank.

    “We believe that the unique combination of biomedical and phenotypic information that has been collected over the past 25 years from a general population rather than a specific disease cohort can help accelerate biomarker discovery and validation,” comments Per Foss, HUNT CEO. “Already, HUNT samples are widely used in academic research, and through this collaboration with Tissue Solutions we aim to significantly increase our pharma and diagnostic industry customer base.”

    HUNT Biosciences has held an exclusive commercial license to the population biobank material collected by the NTNU since 1984. The company is owned by NTNU, the Central Norway Regional Health Authority, and the North Trøndelag County.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »